• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dianthus Therapeutics, Inc. - Common Stock (NQ:DNTH)

88.21 -0.11 (-0.12%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 760,745
Open 89.05
Bid (Size) 36.09 (200)
Ask (Size) 127.12 (100)
Prev. Close 88.32
Today's Range 87.73 - 91.24
52wk Range 32.22 - 117.88
Shares Outstanding 60,648,883
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 01, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
September 29, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire

Performance

52-Week Range 25.2% below 52-week high
88.21
32.2252W Low 117.8852W High
1 Week 3.3% below 1-week high
84.721W Low 91.241W High

Dianthus Therapeutics, Inc. - Common Stock (DNTH) traded between $32.22 and $117.88 over the past 52 weeks and last traded at $88.21, 25.2% below its 52-week high. Over the past week it ranged between $84.72 and $91.24.

Past 12 Months
+0.4%
-17.0%
-5.5%
+3.2%
+122.3%
+138.9%
1W +$0.38
1M -$18.03
3M -$5.13
6M +$2.71
YTD +$48.53
1Y +$51.28

DNTH was +138.9% over the past year, +3.2% over six months, +122.3% year to date, +0.4% in the last week.

12 Months vs Market
DNTH
+138.9%
DIA
+9.9%
SPY
+15.0%
QQQ
+23.7%
IWM
+15.4%

Over the past 12 months DNTH returned +138.9% versus DIA (Dow) +9.9%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +23.7% and IWM (Russell 2000) +15.4%.

Volume & Liquidity 0.93× 3-mo avg
Today 760,745 3-mo avg 820.2K
1W
849.0K
1M
880.5K
3M
820.2K
6M
858.8K
YTD
930.5K
1Y
859.9K

DNTH most recently traded 760,745 shares against a 3-month average daily volume of 820.2K.

More News

Read More
News headline image
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics to Participate in Three Investor Conferences During September
September 01, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results
August 04, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases
August 04, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
August 03, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
July 02, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
June 29, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 02, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics to Participate in Two Investor Conferences
May 26, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing ↗
May 18, 2026
Via The Motley Fool
News headline image
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish ↗
May 18, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally ↗
May 17, 2026
Via The Motley Fool
News headline image
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120% ↗
May 13, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company ↗
May 13, 2026
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally ↗
May 13, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
May 05, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 01, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000 ↗
April 19, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 06, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics CFO Sells $9.5 Million in Stock ↗
April 06, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗
March 18, 2026
Via The Motley Fool
News headline image
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 12, 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough
March 12, 2026
Via Finterra
Topics Economy

Frequently Asked Questions

Is Dianthus Therapeutics, Inc. - Common Stock publicly traded?
Yes, Dianthus Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Dianthus Therapeutics, Inc. - Common Stock trade on?
Dianthus Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Dianthus Therapeutics, Inc. - Common Stock?
The ticker symbol for Dianthus Therapeutics, Inc. - Common Stock is DNTH on the Nasdaq Stock Market
What is the current price of Dianthus Therapeutics, Inc. - Common Stock?
The current price of Dianthus Therapeutics, Inc. - Common Stock is 88.21
When was Dianthus Therapeutics, Inc. - Common Stock last traded?
The last trade of Dianthus Therapeutics, Inc. - Common Stock was at 10/02/26 04:00 PM ET
What is the market capitalization of Dianthus Therapeutics, Inc. - Common Stock?
The market capitalization of Dianthus Therapeutics, Inc. - Common Stock is 5.35B
How many shares of Dianthus Therapeutics, Inc. - Common Stock are outstanding?
Dianthus Therapeutics, Inc. - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap